Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6750 · 1 trial · 9 indications
To assess the safety and tolerability, characterize the DLTs, and determine the MTD and RP2D(s) of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module
To assess the preliminary anti-tumor activity of AZD6750 in combination with other anti-cancer agents.
| Arm | Type | Description |
|---|---|---|
| Module 1 | EXPERIMENTAL | AZD6750 administered intravenously (IV) as a single agent |
| Module 2 | EXPERIMENTAL | AZD6750 given in combination with rilvegostomig (IV) |
| Name | Type | Description |
|---|---|---|
| AZD6750 | DRUG | AZD6750- CD8 guided IL-2 |
| rilvegostomig | DRUG | Rilvegostomig- PD1-TIGIT bispecific antibody |
Inclusion criteria: * Participant ≥ 18 year * ECOG PS of 0 to 1 * Provision of 'archival' tumor specimen * At least one measurable lesion according to RECIST v1.1, * Minimum life expectancy of 12 weeks * Adequate and stable cardiac function * Adequate bone marrow, liver and kidney function * Body w...
Top 20 of 52 competitors
AZD6750 is an investigational small molecule oncology drug being developed by AstraZeneca PLC (ticker AZN). It is in Phase 1 clinical development for melanoma and other select advanced or metastatic solid tumors. AZD6750 has not been approved by the FDA and remains under clinical investigation.
AZD6750 is being studied for the treatment of melanoma, specifically in adult participants with select advanced or metastatic solid tumors. It is an investigational therapy in Phase 1 development and is not approved for any indication. The melanoma study also enrolls patients with other advanced solid tumors.
AZD6750 is made by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the developer of this investigational small molecule oncology asset. The company is currently running a Phase 1 clinical trial of AZD6750 in adult participants with select advanced or metastatic solid tumors.
AZD6750 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial is currently recruiting adult participants with select advanced or metastatic solid tumors, including melanoma, and is designed to investigate safety.
AZD6750 is being evaluated in one active clinical trial, NCT07115043, titled A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors. The Phase 1 trial is recruiting and plans to enroll 120 participants across the United States, Australia, Japan, and South Korea.
AZD6750 is being studied in melanoma and several other advanced or metastatic solid tumors, including non-small cell lung cancer, squamous cell carcinoma of the skin, renal cell carcinoma, Merkel cell carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, gastric or gastroesophageal junction cancer, and high grade serous ovarian carcinoma.